ACI 35

Drug Profile

ACI 35

Alternative Names: Anti-pTau vaccine - AC Immune

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AC Immune
  • Developer AC Immune; Janssen Pharmaceuticals
  • Class Alzheimer vaccines
  • Mechanism of Action Immunostimulants; Tau protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Alzheimer's-disease in United Kingdom (Parenteral)
  • 30 Jun 2017 AC Immune completes a phase I trial in Alzheimer's disease in Finland and United Kingdom (ISRCTN13033912)
  • 17 Mar 2017 Phase-I clinical trials in Alzheimer's disease in Finland (Parenteral) before March 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top